Transgene Biotek Limited

Equities

TRABI6

INE773D01018

Biotechnology & Medical Research

Market Closed - Bombay S.E. Other stock markets 03:30:53 09/05/2024 pm IST			5-day change	1st Jan Change
6.55 ^INR	-4.38%		-7.36%	-33.64%

14/02	Transgene Biotek Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Transgene Biotek Limited Reports Earnings Results for the Second Quarter Ended September 30, 2023	CI

Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2021

August 14, 2021 at 12:09 pm IST

Transgene Biotek Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 438,470 compared to INR 438,470 a year ago. Net loss was INR 26.117 million compared to INR 26.369 million a year ago. Basic and diluted loss per share was INR 0.34 compared to INR 0.35 a year ago.

Latest news about Transgene Biotek Limited

Transgene Biotek Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter Ended September 30, 2023	14/11	CI
Transgene Biotek Limited Approves Closure of Subsidiary Company Peroral Bio Private Limited	05/23/05	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	05/23/05	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/23/30	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/23/30	CI
Transgene Biotek Limited Reports Earnings Results for the Third Quarter Ended December 31, 2022	14/23/14	CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	12/22/12	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/22/30	CI
Transgene Biotek Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/22/30	CI
Transgene Biotek Limited Reports Earnings Results for the Third Quarter Ended December 31, 2021	14/22/14	CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/21/12	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	14/21/14	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	29/21/29	CI
Transgene Biotek : in Pact to Provide Oral, Nasal Formulations for COVID-19 Vaccine	18/21/18	MT
Transgene Biotek Limited Reports Unaudited Standalone Earnings Results for the Third Quarter Ended December 31, 2020	23/21/23	CI
Transgene Biotek : Incorporates New Subsidiary	28/20/28	MT
Transgene Biotek Limited Announces Address Changes	10/20/10	CI
Transgene Biotek Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2020	10/20/10	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	24/20/24	CI
Transgene Biotek Limited Announces Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2020	03/20/03	CI
Transgene Biotek Limited Approves Licensing Agreement of TrabiORAL Technology with GVK Bio	28/20/28	CI
Transgene Biotek Limited Announces Unaudited Standalone Earnings Results for the Third Quarter Ended December 31, 2019	04/20/04	CI
Transgene Biotek Limited Announces Management Changes	12/19/12	CI

Chart Transgene Biotek Limited

Duration

Period

More charts

Company Profile

Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

Sector

Biotechnology & Medical Research

Calendar

27/05/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TRANSGENE BIOTEK LIMITED	-33.64%	6.22M
MODERNA, INC.	+25.54%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-1.13%	41.52B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.11%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.88%	19.26B
BIO-TECHNE CORPORATION	+0.59%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.41%	12.08B
MEDPACE HOLDINGS, INC.	+26.83%	11.98B

Other Biotechnology & Medical Research